|
Source – Druginfozone - The European Medicines Agency (EMEA) has issued a positive opinion to approve marketing authorisation of Keppra® (levetiracetam) Concentrate (100 mg/mL) as an intravenous administration and for use as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children of four years of age and older with epilepsy.
For more information go to: http://www.druginfozone.nhs.uk/record%20viewing/viewRecord.aspx?id=56026 3
Date of Preparation: 7th February 2006
|
